A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

ClinicalTrials.gov ID: NCT04104776

Public ClinicalTrials.gov record NCT04104776. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.

Study identification

NCT ID: NCT04104776
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 300 participants

Conditions and interventions

Conditions

Interventions

Tulmimetostat Drug
Enzalutamide Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 17, 2019
Primary completion: Feb 26, 2030
Completion: Feb 26, 2030
Last update posted: Aug 18, 2026

2019 – 2030

United States locations

U.S. sites: 22
U.S. states: 13
U.S. cities: 18

Facility	City	State	ZIP	Site status
H. Lee Moffitt Cancer Center & Research Institute	Tampa	Florida	33612	Withdrawn
Winship Cancer Institute of Emory University	Atlanta	Georgia	30322-1013	Recruiting
University of Chicago Medical Center	Chicago	Illinois	60637	Recruiting
Loyola University Medical Center	Maywood	Illinois	60153	Withdrawn
University of Maryland Greenebaum Cancer Center	Baltimore	Maryland	21201	Withdrawn
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215-5450	Completed
University of Michigan Hospitals	Ann Arbor	Michigan	48109	Withdrawn
South Texas Accelerated Research Therapeutics (START) - Midwest Location	Grand Rapids	Michigan	49546	Active, not recruiting
Hackensack University Medical Center	Hackensack	New Jersey	07601	Completed
Roswell Park Cancer Institute	Buffalo	New York	14263-0001	Withdrawn
Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York	New York	10016	Completed
Memorial Sloan Kettering Cancer Center - NYC	New York	New York	10065	Withdrawn
Weill Medical College of Cornell University	New York	New York	10065	Withdrawn
University of Rochester Medical Center, James P. Wilmot Cancer Center	Rochester	New York	14642	Withdrawn
Montefiore Medical Center, Montefiore Medical Center Laboratories	The Bronx	New York	10467-2490	Withdrawn
University of Cincinnati Medical Center	Cincinnati	Ohio	45219	Withdrawn
Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
South Texas Accelerated Research Therapeutics	San Antonio	Texas	78229	Completed
University of Virginia Health System	Charlottesville	Virginia	22908	Recruiting
Swedish Cancer Institute	Seattle	Washington	98104	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109-1023	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04104776, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 18, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04104776 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →